tbuckley/cabot-search huggingface dataset:
Disease Burden in Osteoarthritis Is Similar to That of Rheumatoid Arthritis at Initial Rheumatology Visit and Significantly Greater Six Months Later
Authors: Jacquelin R. Chua, Shakeel Jamal, Mariam Riad, Isabel Castrejon, Anne‐Marie Malfait, Joel A. Block, Theodore Pincus
Journal: Arthritis & Rheumatology (2019)

Objective To analyze disease burden in osteoarthritis (OA) according to Multidimensional Health Assessment Questionnaire (MDHAQ)/Routine Assessment of Patient Index Data 3 (RAPID3) scores at the initial visit and the 6‐month follow‐up visit, compared with rheumatoid arthritis (RA) as a benchmark for high disease burden. Methods All patients with all diagnoses at the Rush University Medical Center Division of Rheumatology complete a paper MDHAQ at all visits, saved as a PDF in the electronic health record. MDHAQ 0–10 scores for physical function, pain, and patient global assessment (compiled into RAPID3 0–30 scores) and additional scales at the initial and 6‐month follow‐up visits, for new OA and RA patients seen from 2011 to 2017, were compared. OA and RA patients were classified as self‐referred or physician‐referred, and RA patients were classified as disease‐modifying antirheumatic drug (DMARD)–naive or having prior‐DMARD treatment. Patient groups were compared using t ‐tests and analysis of variance, adjusted for age, disease duration, body mass index (BMI), education, and ethnicity. Results Compared with RA patients, OA patients had higher age, BMI, and disease duration. At initial visit, the mean RAPID3 did not differ significantly in OA versus DMARD‐naive RA patients, whether self‐ or physician‐referred (range 14.8–16.4 [ P = 0.38]), or in all OA patients versus DMARD‐naive RA patients versus prior‐DMARD RA patients (15.0, 15.7, and 15.8, respectively [ P = 0.49]). After 6 months, RAPID3 was improved to 13.3, 10.3, and 10.8, respectively, which represented substantially greater improvement in RA patients than OA patients ( P &lt; 0.001). Similar results were seen for most self‐reported measures and in adjusted analyses. Conclusion MDHAQ/RAPID3 scores are similar in OA and RA patients at the initial visit, but higher in OA patients than in RA patients 6 months later, reflecting superior RA treatments. The same MDHAQ/RAPID3 allows comparisons of disease burdens in different diseases.
Clinical Significance of Sex Chromosome Loss in Sex-Mismatched Bone Marrow Transplantations: A Potential Candidate for Predicting Adverse Prognosis
Authors: Joon Hee Lee, Jong Do Seo, Dajeong Jeong, Jiwon Yun, Sang-A Kim, Dong-Yeop Shin, Sung-Soo Yoon, Dong Soon Lee
Journal: Blood (2018)
Association between potassium levels and mortality risk in hypertensive patients with or without electrocardiographic left ventricular hypertrophy
Authors: Karoline H Janniche, Christina J Lee, Lærke R Korup, Anna E Aldenryd, Rikke Hansen, Steen M Hansen, Morten W Skov, Adrian H Pietersen, Jonas B Nielsen, Claus Graff, Peter Søgaard, Christian Torp-Pedersen, Christoffer Polcwiartek
Journal: Circulation (2018)

Introduction: Knowledge on optimal potassium levels in relation to hypertension with evidence of left ventricular hypertrophy (LVH) remains limited. Therefore, we investigated the association and i...
Targeted co-delivery of protein and drug to a tumor in vivo by sophisticated RGD-modified lipid-calcium carbonate nanoparticles
Authors: Jian Qing Peng, Shintaro Fumoto, Tadaharu Suga, Hirotaka Miyamoto, Naotaka Kuroda, Shigeru Kawakami, Koyo Nishida
Journal: Journal of Controlled Release (2019)
Abstract 5348: T-type Ca2+ Channels Play A Crucial Role In The Development Of Cardiac Automaticity And Conduction-system: Implication Of Their Time- And Space-dependent Expression
Authors: Einosuke Mizuta, Junichiro Miake, Kyoko Hidaka, Manabu Shirai, Toshihiro Hamada, Osamu Igawa, Chiaki Shigemasa, Takayuki Morisaki, Ichiro Hisatome
Journal: Circulation (2008)

(Background) T-type Ca2+ channels encoded by Cav3.1 or Cav3.2 are abundantly expressed in cardiac pacemaker cells and conduction-system cells to play the pivotal role for cardiac automaticity. The expressions are developmentally regulated, as indicated by their higher density in embryonic heart than in adult heart, however, the precise expressions in a time- and space-dependent manner are unknown during differentiation to heart. (Materials and Methods) To investigate the expression in a time dependent manner, we used Nkx2.5/GFP(+) cardiac progenitor cells derived from mouse embryonic stem (ES) cell, sorted from the embryonic bodies (EBs) with flow cytometers. The current density of each channel was measured by patch-clamp techniques. Moreover we used whole mount in situ hybridization (WISH) technique to investigate the distribution in a space dependent manner. (Results) On the day 7.5 after Nkx2.5/GFP(+) ES cells differentiation, the EBs started the self-directive beating, and the cells predominantly reve...
Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation
Authors: Christina Rautenberg, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, Esther Schuler, Norbert Gattermann, Guido Kobbe, Rainer Haas, Thomas Schroeder
Journal: Blood (2017)
Use of Combat Casualty Care Data to Assess the US Military Trauma System During the Afghanistan and Iraq Conflicts, 2001-2017
Authors: Jeffrey T. Howard, Russ S. Kotwal, Caryn A. Stern, Jud C. Janak, Edward L. Mazuchowski, Frank K. Butler, Zsolt T. Stockinger, Barbara R. Holcomb, Raquel C. Bono, David J. Smith
Journal: JAMA Surgery (2019)

Although the Afghanistan and Iraq conflicts have the lowest US case-fatality rates in history, no comprehensive assessment of combat casualty care statistics, major interventions, or risk factors has been reported to date after 16 years of conflict.To analyze trends in overall combat casualty statistics, to assess aggregate measures of injury and interventions, and to simulate how mortality rates would have changed had the interventions not occurred.Retrospective analysis of all available aggregate and weighted individual administrative data compiled from Department of Defense databases on all 56 763 US military casualties injured in battle in Afghanistan and Iraq from October 1, 2001, through December 31, 2017. Casualty outcomes were compared with period-specific ratios of the use of tourniquets, blood transfusions, and transport to a surgical facility within 60 minutes.Main outcomes were casualty status (alive, killed in action [KIA], or died of wounds [DOW]) and the case-fatality rate (CFR). Regression, simulation, and decomposition analyses were used to assess associations between covariates, interventions, and individual casualty status; estimate casualty transitions (KIA to DOW, KIA to alive, and DOW to alive); and estimate the contribution of interventions to changes in CFR.In aggregate data for 56 763 casualties, CFR decreased in Afghanistan (20.0% to 8.6%) and Iraq (20.4% to 10.1%) from early stages to later stages of the conflicts. Survival for critically injured casualties (Injury Severity Score, 25-75 [critical]) increased from 2.2% to 39.9% in Afghanistan and from 8.9% to 32.9% in Iraq. Simulations using data from 23 699 individual casualties showed that without interventions assessed, CFR would likely have been higher in Afghanistan (15.6% estimated vs 8.6% observed) and Iraq (16.3% estimated vs 10.1% observed), equating to 3672 additional deaths (95% CI, 3209-4244 deaths), of which 1623 (44.2%) were associated with the interventions studied: 474 deaths (12.9%) (95% CI, 439-510) associated with the use of tourniquets, 873 (23.8%) (95% CI, 840-910) with blood transfusion, and 275 (7.5%) (95% CI, 259-292) with prehospital transport times.Our analysis suggests that increased use of tourniquets, blood transfusions, and more rapid prehospital transport were associated with 44.2% of total mortality reduction. More critically injured casualties reached surgical care, with increased survival, implying improvements in prehospital and hospital care.
Permanent Hydrophilization and Generic Bioactivation of Melt Electrowritten Scaffolds
Authors: Sarah Bertlein, Gernot Hochleitner, Michael Schmitz, Jörg Tessmar, Michael Raghunath, Paul D. Dalton, Jürgen Groll
Journal: Advanced Healthcare Materials (2019)

Abstract Melt electrowriting (MEW) is an emerging additive manufacturing technology that direct‐writes low‐micron diameter fibers into 3D scaffolds with high porosities. Often, the polymers currently used for MEW are hydrophobic thermoplastics that induce unspecific protein adsorption and subsequent uncontrolled cell adhesion. Here are developed a coating strategy for MEW scaffolds based on six‐arm star‐shaped NCO‐poly(ethylene oxide‐ stat ‐propylene oxide) (sP(EO‐ stat ‐PO)). This permanently hydrophilizes the PCL through the formation of a hydrogel coating and minimizes unspecific interactions with proteins and cells. It also provides the option of simultaneous covalent attachment of bioactive molecules through reaction with isocyanates before these are hydrolyzed. Furthermore, a photoactivatable chemical functionalization is introduced that is not dependent on the time‐limited window of isocyanate chemistry. For this, photo‐leucine is covalently immobilized into the sP(EO‐ stat ‐PO) layer, resulting in a photoactivatable scaffold that enables the binding of sterically demanding molecules at any timepoint after scaffold preparation and coating and is decoupled from the isocyanate chemistry. A successful biofunctionalization of MEW scaffolds via this strategy is demonstrated with streptavidin and collagen as examples. This hydrogel coating system is a generic one that introduces flexible specific and multiple surface functionalization, potentially for a spectrum of polymers made from different manufacturing processes.
Downregulation of RNF128 activates Wnt/β-catenin signaling to induce cellular EMT and stemness via CD44 and CTTN ubiquitination in melanoma
Authors: Chuan-Yuan Wei, Meng-Xuan Zhu, Yan-Wen Yang, Peng-Fei Zhang, Xuan Yang, Rui Peng, Chao Gao, Jia-Cheng Lu, Lu Wang, Xin-Yi Deng, Nan-Hang Lu, Fa-Zhi Qi, Jian-Ying Gu
Journal: Journal of Hematology & Oncology (2019)

Ring finger proteins (RNFs) were involved in carcinogenesis. Here, we aimed to explore the detailed mechanism of RNF128 in the progression of melanoma. We reanalyzed several gene expression profiles from the Gene Expression Omnibus (GEO) database and obtained the overlapped differential expressed RNF genes. Among them, RNF128 was selected to further explore its expression, the biological significance, and the underlying molecular mechanism, as well as the clinical relevance in melanoma patients. RNF128 was found to be significantly downregulated in the selected datasets, which was further verified in our melanoma tissues. Moreover, RNF128 downregulation was shown to correlate with the malignant phenotype of melanoma, and further functional assays demonstrated that low levels of RNF128 promoted melanoma progression via inducing cell epithelial-mesenchymal transition (EMT) and the acquisition of stemness. Mechanistically, RNF128 interference activated the Wnt pathway via simultaneously ubiquitinating CD44/cortactin (CTTN), resulting in CD44 and c-Myc transcription, thus revealed that RNF128 participated in a positive feedback of the Wnt pathway-CD44 loop. Clinically, we found that patients expressing low RNF128 and high CD44/CTTN levels had a poor prognosis. Downregulated RNF128 activates Wnt signaling to induce cellular EMT and stemness by ubiquitinating and degrading CD44/CTTN, and RNF128 is a reliable diagnostic and prognostic biomarker, and a deeper understanding of RNF128 may contribute to the treatment of melanoma.
Building a tuberculosis-free world: The Lancet Commission on tuberculosis
Authors: Michael J A Reid, Nimalan Arinaminpathy, Amy Bloom, Barry R Bloom, Catharina Boehme, Richard Chaisson, Daniel P Chin, Gavin Churchyard, Helen Cox, Lucica Ditiu, Mark Dybul, Jeremy Farrar, Anthony S Fauci, Endalkachew Fekadu, Paula I Fujiwara, Timothy B Hallett, Christy L Hanson, Mark Harrington, Nick Herbert, Philip C Hopewell, Chieko Ikeda, Dean T Jamison, Aamir J Khan, Irene Koek, Nalini Krishnan, Aaron Motsoaledi, Madhukar Pai, Mario C Raviglione, Almaz Sharman, Peter M Small, Soumya Swaminathan, Zelalem Temesgen, Anna Vassall, Nandita Venkatesan, Kitty van Weezenbeek, Gavin Yamey, Bruce D Agins, Sofia Alexandru, Jason R Andrews, Naomi Beyeler, Stela Bivol, Grania Brigden, Adithya Cattamanchi, Danielle Cazabon, Valeriu Crudu, Amrita Daftary, Puneet Dewan, Laurie K Doepel, Robert W Eisinger, Victoria Fan, Sara Fewer, Jennifer Furin, Jeremy D Goldhaber-Fiebert, Gabriela B Gomez, Stephen M Graham, Devesh Gupta, Maureen Kamene, Sunil Khaparde, Eunice W Mailu, Enos O Masini, Lorrie McHugh, Ellen Mitchell, Suerie Moon, Michael Osberg, Tripti Pande, Lea Prince, Kirankumar Rade, Raghuram Rao, Michelle Remme, James A Seddon, Casey Selwyn, Priya Shete, Kuldeep S Sachdeva, Guy Stallworthy, Juan F Vesga, Valentina Vilc, Eric P Goosby
Journal: The Lancet (2019)
Using science to sell apps: Evaluation of mental health app store quality claims
Authors: Mark Erik Larsen, Kit Huckvale, Jennifer Nicholas, John Torous, Louise Birrell, Emily Li, Bill Reda
Journal: npj Digital Medicine (2019)

Abstract Despite the emergence of curated app libraries for mental health apps, personal searches by consumers remain a common method for discovering apps. App store descriptions therefore represent a key channel to inform consumer choice. This study examined the claims invoked through these app store descriptions, the extent to which scientific language is used to support such claims, and the corresponding evidence in the literature. Google Play and iTunes were searched for apps related to depression, self-harm, substance use, anxiety, and schizophrenia. The descriptions of the top-ranking, consumer-focused apps were coded to identify claims of acceptability and effectiveness, and forms of supporting statement. For apps which invoked ostensibly scientific principles, a literature search was conducted to assess their credibility. Seventy-three apps were coded, and the majority (64%) claimed effectiveness at diagnosing a mental health condition, or improving symptoms, mood or self-management. Scientific language was most frequently used to support these effectiveness claims (44%), although this included techniques not validated by literature searches (8/24 = 33%). Two apps described low-quality, primary evidence to support the use of the app. Only one app included a citation to published literature. A minority of apps (14%) described design or development involving lived experience, and none referenced certification or accreditation processes such as app libraries. Scientific language was the most frequently invoked form of support for use of mental health apps; however, high-quality evidence is not commonly described. Improved knowledge translation strategies may improve the adoption of other strategies, such as certification or lived experience co-design.
NOVEL-1st: A Non-Interventional, Multi-Center Observational Study to Assess the Safety and Efficacy of Nilotinib in Newly Diagnosed Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) in Taiwan
Authors: Hwang Wen-Li, Tsung-Chih Chen, Shyuann-Yuh Lin, Ming-Chih Chang, Pei-Ching Hsiao, Li-Yuan Bai, Ching-Yuan Kuo, Yeu-Chin Chen, Ta-Chih Liu, Jyh-Pyng Gau, Po-Nan Wang, Chieh-Wen Chen, Yee-Ming Lee, Fan-Chen Ku, Jih-Luh Tang
Journal: Blood (2020)
Considerations to Guide Treatment Decisions for Infants Born Weighing Less Than 400 g
Authors: John D. Lantos
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
CLO19-046: Follow-Up and Diagnosis of Breast Incidentalomas on Abdominal and Chest MRI
Authors: Samantha Rios, Kelsey Larson
Journal: Journal of the National Comprehensive Cancer Network (2019)

With the increasing use of medical imaging, it is important to report and appropriately recommend work up for incidental findings. The aim of the study was to understand how often incidental breast findings are identified on MRI chest/abdomen protocols, how these findings are followed, and the final diagnosis (benign vs malignant) of these lesions. A single institution retrospective review was performed of women who underwent abdominal or chest MRI from January 2007–January 2017 for a non–breast cancer reason with a radiologic report containing the key word “breast.” Incidental breast findings were defined as lesions not known or suspected prior to imaging. For all patients where a breast lesion was identified, the radiologic reports, follow-up imaging and procedures, and final breast pathology were reviewed. Descriptive points were analyzed using counts and percentages versus mean with standard deviation where applicable. After review, 261 patients met inclusion and exclusion criteria with demographics in Table 1. Most patients (92%) had a known or benign breast finding, but 8% (n=21) had a breast finding for which follow-up was recommended. Recommendation for follow-up included ultrasound (n=4), mammogram (n=8), per clinician (n=14), and breast MRI (n=2). Only 7/21 (33.3%) completed recommended follow-up: 86% (6/7) had normal imaging and 14% (1/7) had a new breast cancer diagnosed. Thus, the rate of new breast cancer diagnosis from abnormal abdominal or chest MRI was 4.7%. Recommendation for specific imaging follow-up (56%) (mammogram/ultrasound/MRI) in the original MRI report was 39% more likely to be completed versus “per clinician” (17%) recommendation ( P =.15). Incidental breast findings on abdominal and chest MRI are uncommon, but follow-up is important to exclude new breast cancer diagnosis. Specific imaging recommendations (versus “per clinician”) appeared to improve rate of follow-up. Prior studies have looked at incidental breast findings on CT but few have assessed breast incidentalomas on abdominal MRIs, with similar rates of new breast cancer diagnosis documented in our study. Studies assessing breast incidentalomas on chest MRIs are lacking. Going forward, multi-institutional studies may further define the rate of breast cancer diagnosis after breast incidentalomas identified on abdominal/chest MRI. In addition, studies focusing on improving follow-up imaging rates are important for patient safety and quality of care.
Author Correction: Adrenergic nerve degeneration in bone marrow drives aging of the hematopoietic stem cell niche
Authors: Maria Maryanovich, Ali H. Zahalka, Halley Pierce, Sandra Pinho, Fumio Nakahara, Noboru Asada, Qiaozhi Wei, Xizhe Wang, Paul Ciero, Jianing Xu, Avigdor Leftin, Paul S. Frenette
Journal: Nature Medicine (2019)
HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)
Authors: Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, Manish Kohli
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Four large RCTs (ASSURE, S-TARC, PROTECT, ATLAS) tested adjuvant VEGF-TKI therapy in high risk RCC. The results were variable for efficacy and there were concerns for increased toxicity and decline in quality of life (QoL). We performed an updated meta-analysis including results of ATLAS trial to asses a risk-benefit for adjuvant post-operative treatments in high risk RCC patients by assessing reported disease-free survival (DFS), overall survival (OS), and toxicity endpoints. Methods: Literature search was done using Medline, CENTRAL, and Embase. The DerSimonian and Laird random effects model was used to pool estimates for DFS, OS, and common side effects across the 4 trials. A subgroup analysis was performed for sunitinib alone because of its FDA approval. Heterogeneity was assessed with Cochrane Q statistic and was quantified with I 2 test. Risk for bias was assessed using the Cochrane Collaboration’s tool. Results: The 4 RCTs included 4,820 patients. Adjuvant therapy with TKIs yielded no significant improvement in DFS or OS as compared to placebo (DFS HR=0.916; 95% CI, 0.832–1.009 and OS HR=1.09; 95% CI, 0.886–1.150). Separate analysis of DFS in sunitinib vs placebo did not show any benefit (2 studies, N=1,909; HR=0.90; 95% CI, 0.67–1.19). Use of TKIs was associated with significantly increased risk of drug toxicity. Increased risk of grade 3 or 4 adverse events (RR=5.110; 95% CI, 3.765–6.935), diarrhea (RR=10.725; 95% CI, 4.672–24.622), fatigue (RR=3.310; 95% CI, 1.879–5.829), hypertension (RR=4.274; 95% CI, 3.452–5.292) and palmar/plantar dysesthesia (RR=20.53; 95% CI, 9.006–46.801) was observed. There was no statistically significant heterogeneity amongst included trials. QoL endpoints were inconsistently reported. Risk of bias was low. Conclusions: This pooled analysis provides further evidence that there is no OS or DFS benefit associated with adjuvant TKI treatment. There was a significantly increased risk of grade 3 or 4 toxicity in greater than half of the patient population leading to decline in QoL during TKI therapy. Carefully selected very high-risk patients who can tolerate these agents without dose modifications may benefit from adjuvant TKI approach.
Discovery and Characterization Of a Highly Specific Antibody Inhibitor Of Plasma Kallikrein
Authors: Jon A Kenniston, Daniel J Sexton, Diana Martik, Ryan R Faucette, Malini Viswanathan, Niksa Kastrapeli, Kris J Kopacz, Greg P Conley, Allison P Lindberg, Janja Cosic, Stephen R Comeau, Shauna Mason, Mike DiLeo, Jie Chen, Robert C Ladner, Thomas E Edwards, Christopher TenHoor, Andrew E Nixon, Burt Adelman
Journal: Blood (2013)
First-in-Human Clinical Trial to Determine the Safety and Potency of Inducible T Regulatory Cells after Allogeneic Hematopoietic Cell Transplantation
Authors: Margaret L. MacMillan, Keli Lee Hippen, David H. McKenna, Todd E. DeFor, Erica D. Warlick, Claudio G Brunstein, Jeffrey S. Miller, Daniel J. Weisdorf, Bruce R. Blazar, John E. Wagner
Journal: Blood (2018)